Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
KROS | $58.345 -1.03% -1.04% 350K
|
Health Technology
|
| O: -0.36%
H: 2.91%
C: -2.8%
results trial phase 3 phase 1 phase 2 preclinical pre-clinical
Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: -6.0%
H: 2.84%
C: -5.67%
positive results phase 3 trial topline
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 1.53%
H: 0.03%
C: -1.35%
biotech phase 3
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 0.0%
H: 2.47%
C: -19.01%
phase 3 phase 1 phase 2 t-cell
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Published: 2020-12-07 (Crawled : 12:02) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 61.9%
H: 0.0%
C: -31.37%
positive results phase 3 fibromyalgia
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: 2.13%
H: 8.6%
C: 6.34%
cancer therapy treatment phase 3 phase 1 phase 2
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
Published: 2020-12-05 (Crawled : 22:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
| Email alert
Add to watchlist
results phase 3 phase 1 phase 2
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
Published: 2020-12-05 (Crawled : 20:04) - globenewswire.com
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
| Email alert
Add to watchlist
leukemia phase 3 phase 1 phase 2
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome
Published: 2020-12-05 (Crawled : 18:01) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
| Email alert
Add to watchlist
phase 3 phase 1 phase 2 syndros
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Published: 2020-12-05 (Crawled : 18:00) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
| Email alert
Add to watchlist
therapy positive results phase 3 phase 1 phase 2 t-cell
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
Published: 2020-12-04 (Crawled : 21:03) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
| Email alert
Add to watchlist
positive phase 3 phase 1 phase 2 t-cell
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Published: 2020-12-04 (Crawled : 15:00) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -4.69%
H: 2.36%
C: -14.82%
positive results leukemia trial phase 3 phase 1 phase 2 t-cell
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Published: 2020-09-08 (Crawled : 12:07) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K
|
Health Technology
|
| O: 3.35%
H: 54.43%
C: 41.14%
positive results phase 3 trial topline injection infections
Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma
Published: 2020-12-04 (Crawled : 06:01) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 3.87%
H: 0.69%
C: -2.98%
trial phase 3 phase 1 phase 2
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Published: 2020-12-03 (Crawled : 17:00) - biospace.com/
EYEN | $0.574 8.12% 7.51% 1.4M
|
Health Technology
|
| O: 3.66%
H: 1.63%
C: -1.9%
fda eye phase 3 trial fda acceptance presbyopia
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2020-12-03 (Crawled : 16:00) - biospace.com/
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.41%
H: 2.21%
C: 0.9%
phase 3 treatment enroll
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
Published: 2020-03-31 (Crawled : 15:41) - globenewswire.com
ITRM | $1.43 -0.69% 60K
|
Health Technology
|
| O: 1.79%
H: 1.75%
C: -4.91%
phase 3 trial sulopenem injection infections
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
Published: 2020-06-01 (Crawled : 15:41) - globenewswire.com
ITRM | $1.43 -0.69% 60K
|
Health Technology
|
| O: -62.49%
H: 38.7%
C: 7.66%
results phase 3 trial sulopenem topline injection infections
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.